Protalix Biotherapeutics, Inc.
(NYSE Amex Equities : PLX)

( )
PLX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Services » Servicestothe Health Industry
symbolcompany%chnglast%shortavg$volume
LHLaboratory Corporation of America Holdings
0.22%136.002.3%$132.39m
CERNCerner Corporation
2.08%54.087.5%$115.18m
DGXQuest Diagnostics Incorporated
0.16%86.324.2%$103.76m
ATHNathenahealth, Inc.
0.21%134.1517.4%$89.51m
SRCLStericycle, Inc.
1.76%42.786.3%$49.62m
MDRXAllscripts Healthcare Solutions, Inc.
-1.58%11.869.7%$30.41m
HCSGHealthcare Services Group, Inc.
-0.20%43.976.7%$19.79m
OMCLOmnicell, Inc.
-1.53%64.4010.9%$17.12m
HMSYHMS Holdings Corp.
-0.76%28.641.9%$15.90m
CPSIComputer Programs and Systems, Inc.
1.20%27.0132.9%$2.85m
HSTMHealthStream, Inc.
0.12%24.936.7%$1.95m
PMDPsychemedics Corporation
-0.68%17.520.7%$0.24m
PLXProtalix Biotherapeutics, Inc.
-1.16%0.435.8%$0.22m
IDXGInterpace Diagnostics Group, Inc.
-14.07%0.893.3%$0.21m
STRMStreamline Health Solutions, Inc.
0.83%1.220.3%$0.04m

Company Profile

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.